New Risk • Jun 03
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 65% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (195% payout ratio). Large one-off items impacting financial results. Reported Earnings • Apr 29
Full year 2025 earnings released: EPS: CN¥0.25 (vs CN¥0.12 in FY 2024) Full year 2025 results: EPS: CN¥0.25 (up from CN¥0.12 in FY 2024). Revenue: CN¥688.4m (up 26% from FY 2024). Net income: CN¥34.3m (up 101% from FY 2024). Profit margin: 5.0% (up from 3.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Announcement • Apr 29
PharmaResources (Shanghai) Co., Ltd., Annual General Meeting, May 19, 2026 PharmaResources (Shanghai) Co., Ltd., Annual General Meeting, May 19, 2026, at 14:00 China Standard Time. Location: 1F, Building 12, No. 59, Kaiqing Road, Pudong New Area, Shanghai China Announcement • Mar 31
PharmaResources (Shanghai) Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 PharmaResources (Shanghai) Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 New Risk • Feb 02
New major risk - Revenue and earnings growth Earnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 195% Cash payout ratio: 93% Earnings have declined by 24% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. New Risk • Jan 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (156% payout ratio). Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Announcement • Dec 31
PharmaResources (Shanghai) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 PharmaResources (Shanghai) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.07 (vs CN¥0.006 loss in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.07 (up from CN¥0.006 loss in 3Q 2024). Revenue: CN¥161.7m (up 29% from 3Q 2024). Net income: CN¥9.99m (up CN¥10.7m from 3Q 2024). Profit margin: 6.2% (up from net loss in 3Q 2024). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Announcement • Sep 30
PharmaResources (Shanghai) Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 PharmaResources (Shanghai) Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Board Change • Jul 25
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 5 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Li Cheng was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Jul 02
PharmaResources (Shanghai) Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 PharmaResources (Shanghai) Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Declared Dividend • Jun 30
Dividend of CN¥0.33 announced Shareholders will receive a dividend of CN¥0.33. Ex-date: 4th July 2025 Payment date: 4th July 2025 Dividend yield will be 1.2%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is not covered by earnings (246% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 25% per year over the past 2 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 173% to bring the payout ratio under control. EPS is expected to grow by 197% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. New Risk • May 16
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 98% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Dividend is not well covered by earnings and cash flows. Payout ratio: 246% Paying a dividend despite having no free cash flows. Minor Risk Large one-off items impacting financial results. New Risk • May 03
New major risk - Revenue and earnings growth Earnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Dividend is not well covered by earnings and cash flows. Dividend per share is over 7x earnings per share. Paying a dividend despite having no free cash flows. Earnings have declined by 24% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.1% net profit margin). Announcement • Apr 25
PharmaResources (Shanghai) Co., Ltd. Proposes Final Cash Dividend for 2024 PharmaResources (Shanghai) Co., Ltd. proposed final cash dividend of CNY 3.30000000 per 10 shares (tax included) for 2024. Reported Earnings • Apr 24
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.12 (down from CN¥0.27 in FY 2023). Revenue: CN¥544.5m (up 11% from FY 2023). Net income: CN¥17.1m (down 55% from FY 2023). Profit margin: 3.1% (down from 7.7% in FY 2023). Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Life Sciences industry in China. Announcement • Apr 24
PharmaResources (Shanghai) Co., Ltd., Annual General Meeting, May 15, 2025 PharmaResources (Shanghai) Co., Ltd., Annual General Meeting, May 15, 2025, at 14:00 China Standard Time. Location: 1F, Building 12, No. 59, Kaiqing Road, Pudong New Area, Shanghai China Announcement • Mar 31
PharmaResources (Shanghai) Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 PharmaResources (Shanghai) Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Mar 22
Pharmaresources (Shanghai) Co., Ltd. Approves Board Appointments PharmaResources (Shanghai) Co., Ltd. announced at the EGM held on March 20, 2025, approved election of Fei Zheng as non-independent director; Shao Chunyang as independent director; Liu Zeping as non-employee supervisor. New Risk • Feb 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Dividend per share is over 7x earnings per share. Paying a dividend despite having no free cash flows. High level of non-cash earnings (21% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Profit margins are more than 30% lower than last year (1.3% net profit margin). New Risk • Jan 12
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Dec 31
PharmaResources (Shanghai) Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025 PharmaResources (Shanghai) Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025 Announcement • Oct 19
PharmaResources (Shanghai) Co., Ltd. Announces Interim Dividend on A Shares for 2024, Payable on 24 October 2024 PharmaResources (Shanghai) Co., Ltd. announced interim cash dividend of CNY 1.00000000 per 10 A shares (tax included) for 2024. Record date: 23 October 2024. Ex-date: 24 October 2024. Payment date: 24 October 2024. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 246% Paying a dividend despite having no free cash flows. High level of non-cash earnings (28% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Profit margins are more than 30% lower than last year (4.0% net profit margin). Announcement • Sep 30
PharmaResources (Shanghai) Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024 PharmaResources (Shanghai) Co., Ltd. announced that they will report Q3, 2024 results on Oct 28, 2024 Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.093 (vs CN¥0.13 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.093 (down from CN¥0.13 in 2Q 2023). Revenue: CN¥135.0m (up 16% from 2Q 2023). Net income: CN¥12.3m (down 30% from 2Q 2023). Profit margin: 9.1% (down from 15% in 2Q 2023). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Announcement • Jun 29
PharmaResources (Shanghai) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 PharmaResources (Shanghai) Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Declared Dividend • Jun 19
Dividend of CN¥0.33 announced Shareholders will receive a dividend of CN¥0.33. Ex-date: 21st June 2024 Payment date: 21st June 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is not covered by earnings (141% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. The company's earnings per share (EPS) would need to grow by 56% to bring the payout ratio under control. EPS is expected to grow by 77% over the next year, which is sufficient to bring the dividend into a sustainable range. Announcement • Apr 25
PharmaResources (Shanghai) Co., Ltd., Annual General Meeting, May 15, 2024 PharmaResources (Shanghai) Co., Ltd., Annual General Meeting, May 15, 2024, at 14:00 China Standard Time. Location: 1F, Building 12, No. 59, Kaiqing Road, Pudong New Area, Shanghai China Reported Earnings • Apr 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.35 (down from CN¥0.79 in FY 2022). Revenue: CN¥489.7m (up 2.3% from FY 2022). Net income: CN¥37.6m (down 44% from FY 2022). Profit margin: 7.7% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 65%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥29.53, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Life Sciences industry in China. Total loss to shareholders of 31% over the past year. Announcement • Mar 30
PharmaResources (Shanghai) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 PharmaResources (Shanghai) Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to CN¥36.42, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 24x in the Life Sciences industry in China. Total loss to shareholders of 4.0% over the past year. Announcement • Feb 20
PharmaResources (Shanghai) Co., Ltd. (SZSE:301230) announces an Equity Buyback for CNY 100 million worth of its shares. PharmaResources (Shanghai) Co., Ltd. (SZSE:301230) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its A shares. The shares will be purchased at a price not exceeding CNY 45 per share. The repurchased shares will be used for Employees’ shareholding plan or equity incentive plan. The program will be valid for 12 months. Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥33.72, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 20x in the Life Sciences industry in China. Total loss to shareholders of 21% over the past year. New Risk • Jan 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (51% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.8% average weekly change). Announcement • Dec 29
PharmaResources (Shanghai) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024 PharmaResources (Shanghai) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 24, 2024 Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.17 (up from CN¥0.13 in 2Q 2022). Revenue: CN¥116.3m (up 12% from 2Q 2022). Net income: CN¥17.6m (up 70% from 2Q 2022). Profit margin: 15% (up from 10.0% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥51.03, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 25x in the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥52.44, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 26x in the Life Sciences industry in China. Announcement • May 19
PharmaResources (Shanghai) Co., Ltd. Approves Cash Dividend PharmaResources (Shanghai) Co., Ltd. announced that at the AGM was held on 15 May 2023, the company approved the cash dividend/10 shares (tax included): CNY 5.00000000. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.20 (up from CN¥0.18 in 1Q 2022). Revenue: CN¥121.4m (up 16% from 1Q 2022). Net income: CN¥15.3m (up 47% from 1Q 2022). Profit margin: 13% (up from 10.0% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 41% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improves as stock rises 29% After last week's 29% share price gain to CN¥67.80, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 42x in the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥69.90, the stock trades at a trailing P/E ratio of 75x. Average trailing P/E is 57x in the Life Sciences industry in China. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.